bioRxivCancer BiologyPreprint
High Drug-Loading Rucaparib-FdUMP Nanocarriers for Colorectal Cancer Combination Therapy
Anna Erika WeberiD, Christian Ritschel, Claus FeldmanniD, Susanne KossatziD
Abstract
Combination chemotherapy remains the standard of care for advanced colorectal cancer, yet the clinical benefit is limited by off-target toxicity and insufficient tumor drug exposure. Co-administration of 5-fluorouracil (5-FU) with poly(ADP-ribose) polymerase (PARP) inhibitors such as rucaparib (RUC) can potentiate 5-FU-induced DNA damage by suppressing DNA repair but achieving robust co-delivery at defined ratios and high payload remains challenging. Here, we report high drug-loading core@shell nanocarriers (RUC@[ZrO][FdUMP]) that co-deliver RUC and the active 5-FU metabolite fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). Nanocarriers were synthesized via a solvent-antisolvent approach to form a tocopherol phosphate (TocP)-stabilized RUC core followed by the growth of an amorphous [ZrO][FdUMP] shell, yielding an overall drug load of 59 wt%. Dual fluorescence (shell incorporation of DUT647 and intrinsic RUC emission) enabled quantitative tracking and revealed rapid uptake in HCT116 and HT29 colorectal cancer cells and tumor accumulation in a subcutaneous HT29 xenograft. In vitro, RUC@[ZrO][FdUMP] showed cytotoxicity comparable to the free-drug combination, induced S-phase arrest, and increased {gamma}H2AX foci, consistent with replication stress and DNA double-strand break formation. Drug-drug interaction analysis demonstrated synergistic activity of the RUC/FdUMP pair in colorectal cancer cells. Together, these results establish RUC@[ZrO][FdUMP] as a high-payload nanocarrier platform for co-delivering synergistic PARP inhibitor/fluoropyrimidine combinations, supporting further development and in vivo evaluation of this co-delivery strategy for colorectal cancer therapy. TOC Graphics O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=50 SRC="FIGDIR/small/727099v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@dd9ad6org.highwire.dtl.DTLVardef@e07aecorg.highwire.dtl.DTLVardef@1a63505org.highwire.dtl.DTLVardef@e30d58_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cellular uptake of folate-olaparib conjugates via folate receptor-mediated endocytosis: Potential for selective delivery of DNA damage response inhibitors into tumour cells
Vassilios Bavetsias, Lisa Pickard, … Udai Banerji·bioRxiv·Sep 24, 2026
- Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer
L. Wang, J. C. Evans, … C. Allen·bioRxiv·Aug 29, 2022
- Transferrin Receptor 1-targeted polymersomes therapy for Colorectal Cancer
Ariana Pina, Elisa Mastrantuono, … Diana Matias·Materials Today BioPeer-reviewed·Sep 3, 2025
- Novel polymeric fluoropyrimidine CF10 demonstrates superior therapeutic index and survival advantage in patient-derived models of 5-fluorouracil-refractory colorectal cancer
Naresh Sah, Tasmin Rahman Omy, … Komaraiah Palle·bioRxiv·Apr 8, 2026
- Photodynamic therapy in colorectal cancer using photosensitizers functionalized by arene-ruthenium complexes
J. Massoud, A. Pinon, … B. Liagre·bioRxiv·Oct 11, 2022
- Loss-of-Function genetic Screen Unveils Synergistic Efficacy of PARG Inhibition with Combined 5-Fluorouracil and Irinotecan Treatment in Colorectal Cancer
Cristina Queralt, Cristina Moreta-Moraleda, … Eva Martinez‐Balibrea·Clinical and Translational MedicinePeer-reviewed·Dec 1, 2025